The Role of Maximum Standardized Uptake Value in PET/CT as a Prognostic Factor in Patients with Resected Esophageal Squamous Cell Carcinoma

Abstract

Background The aim of this study was to evaluate the role of the maximum standardized uptake value (mSUV) of the main mass as a risk factor for recurrence in patients with completely resected esophageal squamous cell carcinoma (ESCC).

Patients and Methods Clinicopathologic factors including primary tumor location, tumor size, depth of tumor invasion, number of positive lymph nodes, angiolymphatic invasion, and mSUV were analyzed as risk factors for recurrence. The prognostic influence of variables on disease-free survival was analyzed using the log-rank test for univariate analysis and the Cox proportional hazards model for multivariate analysis.

Results A total of 102 patients underwent complete resection of ESCC and positron emission tomography/computed tomography was performed. The median follow-up period was 35.0 months (range, 2–94). The average mSUV of the main mass was 5.5 ± 4.2. The tumor had recurred in 38 patients (37.3%). Univariate analysis identified that tumor size (> 3.5 cm), depth of tumor invasion (≥ T2), pathologic stage, and mSUV (> 5.1) were statistically significant prognostic factors for recurrence of ESCC. However, in multivariate analysis, only mSUV (> 5.1, HR = 4.222, p = 0.025) was the independent risk factor of recurrence.

Conclusions The mSUV of the main mass was an independent predictor for recurrence with a cutoff value of 5.1.

Keywords

maximum standardized uptake value - positron emission tomography/computed tomography - esophageal cancer - prognosis

• References

• 1 Rekkedal G. WHO world health report 1997 [in Norwegian]. Tidsskr Sykepl 1997; 85 (9) 37-39
• 2 Tachibana M, Kinugasa S, Hirahara N, Yoshimura H. Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma. Eur J Cardiothorac Surg 2008; 34 (2) 427-431
• 3 Daly JM, Fry WA, Little AG , et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000; 190 (5) 562-572 , discussion 572–573
• 4 Zhu ZJ, Hu Y, Zhao YF, Chen XZ, Chen LQ, Chen YT. Early recurrence and death after esophagectomy in patients with esophageal squamous cell carcinoma. Ann Thorac Surg 2011; 91 (5) 1502-1508
• 5 Ishihara R, Yamamoto S, Iishi H , et al. Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010; 76 (1) 123-129
• 6 Tachibana M, Kinugasa S, Yoshimura H , et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg 2005; 189 (1) 98-109
• 7 Kim H, Woo J, Kim K, Shim Y. The recurrence and survival after complete resection of esophageal cancer. Korean J Thorac Cardiovasc Surg 2003; 36: 411-417
• 8 Noble F, Bailey D, Tung K, Byrne JP. SWCIS Upper Gastrointestinal Tumour Panel. Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol 2009; 64 (7) 699-705
• 9 Kim MK, Ryu JS, Kim SB , et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 2007; 43 (9) 1385-1391
• 10 Shum WY, Hsieh TC, Yeh JJ , et al. Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma. Eur J Radiol 2012; 81 (5) 1024-1028
• 11 Pifarré-Montaner P, Fernández-León A, de Juan R , et al. Impact of (18)F-FDG PET/CT on the therapeutic management in the initial staging of the esophageal cancer. [in Spanish]. Rev Esp Med Nucl 2009; 28 (3) 101-105
• 12 Liberale G, Van Laethem JL, Gay F , et al. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol 2004; 30 (9) 942-947
• 13 Yasuda S, Raja S, Hubner KF. Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case. Surg Today 1995; 25 (3) 261-264
• 14 Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998; 39 (6) 1002-1007
• 15 Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2009; 21 (9) 1008-1015
• 16 Hsu WH, Hsu PK, Wang SJ , et al. Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma. Ann Thorac Surg 2009; 87 (5) 1564-1568
• 17 Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2006; 82 (2) 391-394 , discussion 394–395
• 18 Cheze-Le Rest C, Metges JP, Teyton P , et al. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study. Nucl Med Commun 2008; 29 (7) 628-635
• 19 Kato H, Nakajima M, Sohda M , et al. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 2009; 115 (14) 3196-3203